Publication

Delivery system for budesonide based on lipid-DNA

Liu, Y., Bos, I. S. T., Oenema, T. A., Meurs, H., Maarsingh, H. & Hirsch, A. K. H., Sep-2018, In : European Journal of Pharmaceutics and Biopharmaceutics. 130, p. 123-127 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Delivery system for budesonide based on lipid-DNA

    Final publisher's version, 743 KB, PDF document

    Request copy

Links

DOI

Budesonide is a hydrophobic glucocorticoid with high anti-inflammatory activity for the treatment of asthma, inflammatory bowel disease and rheumatoid arthritis. A micellar drug-delivery system based on lipid-DNA may provide a strategy to maximize its drug efficacy and reduce adverse effects. In this work, we report the use of lipid-DNAA (UU11mer), featuring two hydrophobic alkyl chains and forming micelles at a comparatively low critical micelle concentration, to render budesonide water-soluble with a high loading capacity (LC). The inhibition of interleukin-8 (IL-8) release shows that the new delivery system retains the inhibitory activity in cell based assays. In conclusion, this research provides a novel approach to formulate and administer budesonide in a non-invasive manner, which dramatically improves its water-solubility while retaining its bioavailability.

Original languageEnglish
Pages (from-to)123-127
Number of pages5
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume130
Publication statusPublished - Sep-2018

    Keywords

  • Drug delivery, Anti-inflammatory, Budesonide, Lipid-DNA, Solubility, AIRWAY SMOOTH-MUSCLE, DRUG-DELIVERY, RHEUMATOID-ARTHRITIS, ULCERATIVE-COLITIS, POLYMERIC MICELLES, CROHNS-DISEASE, ASTHMA, THERAPY, PHARMACOKINETICS, CORTICOSTEROIDS

ID: 65091230